SSY GROUP LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.67 HKD | -0.85% |
|
-2.51% | -5.47% |
| Sales 2024 * | 7.58B 970M | Sales 2025 * | 8.83B 1.13B | Capitalization | 13.98B 1.79B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.57B 201M | Net income 2025 * | 1.84B 236M | EV / Sales 2024 * | 1.84 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.58 x |
| P/E ratio 2024 * |
8.93
x | P/E ratio 2025 * |
7.56
x | Employees | 5,640 |
| Yield 2024 * |
3.61% | Yield 2025 * |
3.82% | Free-Float | 41.1% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.85% | ||
| 1 week | -2.51% | ||
| Current month | -0.85% | ||
| 1 month | -2.30% | ||
| 3 months | -0.21% | ||
| 6 months | -3.71% | ||
| Current year | -5.47% |
1 week
4.65
4.80
1 month
4.585.06
Current year
3.885.20
1 year
3.885.29
3 years
2.508.29
5 years
2.509.00
10 years
1.699.46
| Managers | Title | Age | Since |
|---|---|---|---|
Ji Guang Qu
CEO | Chief Executive Officer | 70 | - |
Hing Yeung Chow
DFI | Director of Finance/CFO | 45 | 15-03-31 |
Guo Meng
BRD | Director/Board Member | 50 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ji Guang Qu
CEO | Chief Executive Officer | 70 | - |
Yi Bing Wang
BRD | Director/Board Member | 61 | 07-07-25 |
Kwok Wai Chow
BRD | Director/Board Member | 57 | 05-10-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.89% | 4 M€ | -27.92% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +4.61% | - | |
| 0.00% | 34 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-02 | 4.67 | -0.85% | 724 000 |
| 24-05-31 | 4.71 | -0.63% | 3,237,000 |
| 24-05-30 | 4.74 | +0.64% | 2,706,000 |
| 24-05-29 | 4.71 | -0.84% | 1,648,000 |
| 24-05-28 | 4.75 | -0.84% | 1,428,000 |
Delayed Quote Hong Kong S.E., June 02, 2024 at 11:54 pm EDT
More quotes
SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Companyâs main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Companyâs products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Companyâs products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.
Sector
Pharmaceuticals
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.71
HKD
Average target price
6.227
HKD
Spread / Average Target
+32.20%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.47% | 1.79B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 2005 Stock
